Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Measurement of tumor necrosis factor-α, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease

Authors Fanny WS Ko, Ting-Fan Leung, Gary WK Wong, Jenny Ngai, Kin W To, et al

Published 10 December 2008 Volume 2009:4 Pages 79—86

DOI https://doi.org/10.2147/COPD.S4158

Review by Single-blind

Peer reviewer comments 3

Fanny WS Ko1, Ting-Fan Leung2, Gary WK Wong2, Jenny Ngai1, Kin W To1, Susanna Ng1, David SC Hui1

1Department of Medicine and Therapeutics; 2Department of Pediatrics, The Chinese University of Hong Kong, Hong Kong

Background: Assessment of airway inflammation in the clinical course of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) may advance our understanding of the pathogenesis and treatment.

Objectives: To assess airway inflammation in patients during the course of AECOPD by serial analyses of their exhaled breath condensates (EBC).

Methods: Twenty-six patients with AECOPD (22 males, mean[SD] percentage predicted forced expiratory volume in one second (FEV1) 44.8 [14.3]), 11 with stable COPD, and 14 age and sex-matched healthy controls were studied. Patients with AECOPD were treated with systemic steroid and antibiotic for 7 days. EBC was collected from each patient with AECOPD on Day 5, 14, 30, and 60 post-hospitalization using EcoScreen (VIASYS Healthcare, USA) during tidal breathing over 10 minutes. Concentrations of tumor necrosis factor-α (TNF-α), leukotriene B4 (LTB4), and interleukin-8 (IL-8) were measured by enzyme-linked immunosorbent assay.

Results: The median (IQR) of TNF-α level on Day 5 was 5.08 (3.80–6 .32) pg/ml, which was lower than on Day 14 (5.84 [4.91–9.14] pg/ml, p = 0.017), Day 30 (6.14 [3.82–7.67] pg/ml, p = 0.045), and Day 60 (5.60 [4.53–8.80] pg/ml, p = 0.009). On Day 60, subjects receiving inhaled corticosteroid (ICS) had a lower level of TNF-α than those who were not (4.82 [4.06–5.65] vs 7.66 [5.48–10.9] pg/ml, p = 0.02). EBC LTB4 level did not change significantly during recovery from AECOPD whereas IL-8 was mostly undetectable.

Conclusions: EBC TNF-α level was low in patients receiving systemic steroid and antibiotic therapy for AECOPD. These findings suggest a potential role for serial EBC TNF-α for noninvasive monitoring of disease activity.

Keywords: COPD, exacerbation, exhaled breath condensate, TNF-α, LTB4

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD

Khorasani N, Baker J, Johnson M, Chung KF, Bhavsar PK

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:283-291

Published Date: 4 February 2015

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency

Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:687-696

Published Date: 28 September 2012

Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity

Joseph Finkelstein, Eunme Cha, Steven M Scharf

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:337-349

Published Date: 4 September 2009

Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation

Erik Bathoorn, Jeroen JW Liesker, Dirkje S Postma, Gerard H Koëter, Marco van der Toorn, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:101-109

Published Date: 2 February 2009

Identifying potentially cost effective chronic care programs for people with COPD

L M G Steuten, K M M Lemmens, A P Nieboer, H JM Vrijhoef

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:87-100

Published Date: 22 December 2008

Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: Current and future perspectives

Noora Louhelainen, Marjukka Myllärniemi, Irfan Rahman, Vuokko L Kinnula

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:585-603

Published Date: 5 December 2008

Non-invasive biomarkers and pulmonary function in smokers

Zoë L Borrill, Kay Roy, Rupert S Vessey, Ashley A Woodcock, Dave Singh

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:171-183

Published Date: 7 March 2008

Rivastigmine in the treatment of Alzheimer's disease: an update

Maria Luisa Onor, Marianna Trevisiol, Eugenio Aguglia

Clinical Interventions in Aging 2007, 2:17-32

Published Date: 15 April 2007